Banner

Reversal Strategies for DOAC-Related Bleeding: Patient Assessment and Current Evidence

With the increasing use of anticoagulants comes the concurrent risk of bleeding complications. In this educational activity, the faculty review the incidence, severity, and cost of bleeding complications related to direct-acting oral anticoagulant (DOAC) therapy, such as intracranial hemorrhage, gastrointestinal bleeding, and bleeding in a critical organ. Case scenarios illustrate a comprehensive patient assessment approach for determining the optimal anticoagulant reversal strategy, and recent clinical evidence regarding the safety and efficacy of DOAC reversal is described.

Learning Objectives

  • Discuss the incidence, severity, and cost of bleeding complications associated with the use of direct-acting anticoagulant (DOAC) therapy.
  • Given patient characteristics, develop a systematic patient assessment approach to identify the optimal anticoagulant reversal strategy.
  • Summarize recent clinical evidence regarding the safety and efficacy of DOAC reversal.

Faculty

James S. Kalus, PharmD, FASHP
Director of Pharmacy
Henry Ford Health System
Detroit, Michigan

Jason R. Vilar, Pharm.D., BCCCP
Neurocritical Care Pharmacy Specialist
AdventHealth Orlando
Orlando, Florida

Target Audience

This educational initiative was planned to meet the educational needs of pharmacists in hospitals and health systems involved in the management of bleeding associated with the use of direct-acting oral anticoagulant therapy.

Format

This online activity consists of slide presentations, active learning, and evaluation. View the system requirements.

Disclosures

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company.

CPE Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE #: 0204-0000-21-402-H01-P
Release Date: Thursday, April 22, 2021
Expiration Date: Friday, May 13, 2022
Activity Type: Application-based
CE Credits: 1.5 hours
Activity Fee: Free of charge

Process CE Within 60 Days

Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.

To receive CE credit, complete the steps below within 60 days of completing the activity.

  1. View entire presentation and answer all polling questions.
  2. Click "Complete Activity" on the last slide to to link to complete the evaluation.
  3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credit(s).